Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- Check15 days agoChange DetectedThe page’s revision label has been updated from v3.5.3 to v3.5.4, indicating a newer build of the page. This update reflects a version change rather than a substantive alteration to the study details.SummaryDifference0.0%

- Check22 days agoChange DetectedA new MARIPOSA publication citation (Lazertinib versus Osimertinib in EGFR-mutant NSCLC; J Thorac Oncol 2025) was added on 2026-05-08. Additionally, May 2026 date entries were added (2026-05-07 and 2026-05), and April 2026 entries (2026-04-22, 2026-04-09, 2026-04) were removed.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check37 days agoChange DetectedThe study locations section was updated to add new sites in China and Turkey and to increase the total number of locations to 269; several previously listed sites were removed (Beijing Cancer Hospital, Hunan Cancer Hospital, Ankara 6560, Gazi University Hospital, National Cancer Institute, The Royal Marsden NHS Trust), reflecting a revision to the study's site roster.SummaryDifference0.3%

- Check45 days agoChange DetectedThe page revision/version indicator was updated from v3.5.0 to v3.5.2. No study content or key details were changed.SummaryDifference0.0%

- Check73 days agoChange DetectedNapoli, Italy 80100 was replaced with Naples, Italy 80100. The Naples location was added and Napoli removed; page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check88 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.